Declining sales of Humira due to biosimilar erosion.
7 reports, 4 independent
Updated Sep 4
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 7
- Developments
- 3
- Repetition
- 71%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Declining sales of Humira due to biosimilar erosion.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Lost patent protection for Humira in the US on August 20, 2025.Sub-event
Humira sales are declining due to biosimilar competition.1 source
Analysts question Humira's future and the growth of AbbVie's other drugs due to biosimilar competition.1 source
Keep exploring
The entities involved
Related events
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- BarchartIs AbbVie Stock Underperforming the S&P 500? North Chicago, Illinois-based AbbVie Inc. (ABBV) discovers, develops, manufactures, and sells pharmaceuticals worldwide. With a market cap of $371.7 billi
- StockStory5 Insightful Analyst Questions From AbbVie’s Q2 Earnings Call AbbVie’s second quarter saw a significant positive market response, driven by robust sales from its immunology and neuroscience portfolio
- StockStoryABBV Q2 Deep Dive: Immunology and Neuroscience Growth Outpace Aesthetics, Guidance Trimmed Pharmaceutical company AbbVie (NYSE:ABBV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025,
- Motley FoolThe Smartest Dividend Stocks to Buy With $300 Right Now AbbVie is a Dividend King that has something to offer income, value, and growth investors. With market valuations at frothy levels, Dominion En